INSILICO Shares Surge Nearly 6% Following Strategic Collaboration Intent with UAE Health Authority

Stock News03-05 10:38

INSILICO (03696) rose nearly 6%, with gains reaching 5.81% at the time of writing, trading at HK$54.65 and recording a turnover of HK$40.6374 million. On March 5, the company announced via its official social media account that it has formally signed a memorandum of understanding (MOU) with the UAE's Emirates Drug Establishment (EDE) to deepen the development of the pharmaceutical industry in the UAE through AI-driven drug discovery and development technologies. The collaboration was established during WHX 2026 (World Health Expo 2026), aiming to leverage the strengths of both parties and expand cooperation areas, with the goal of building the UAE's independent pharmaceutical R&D capabilities, supporting the evaluation and management of innovative medical products, and enabling knowledge sharing and professional training to foster collaboration with local research institutions. WHX 2026 was held from February 9 to 12, 2026, at Dubai Expo City, where INSILICO was invited by EDE to deliver a keynote speech at its exhibition booth, showcasing the core role of AI and automation technologies in accelerating drug development through interactive demonstrations. Previously, INSILICO established an AI and quantum computing drug R&D center in Abu Dhabi. As one of the largest AI-driven research hubs in the Middle East, the center is dedicated to advancing drug discovery and the development of its Pharma.AI platform, strengthening cross-disciplinary innovation in AI and life sciences.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1163799838?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 10:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163799838","market":"other","top_or_hot":-1,"title":"INSILICO Shares Surge Nearly 6% Following Strategic Collaboration Intent with UAE Health Authority","media":"Stock News","content":"<p>INSILICO (03696) rose nearly 6%, with gains reaching 5.81% at the time of writing, trading at HK$54.65 and recording a turnover of HK$40.6374 million. On March 5, the company announced via its official social media account that it has formally signed a memorandum of understanding (MOU) with the UAE's Emirates Drug Establishment (EDE) to deepen the development of the pharmaceutical industry in the UAE through AI-driven drug discovery and development technologies. The collaboration was established during WHX 2026 (World Health Expo 2026), aiming to leverage the strengths of both parties and expand cooperation areas, with the goal of building the UAE's independent pharmaceutical R&D capabilities, supporting the evaluation and management of innovative medical products, and enabling knowledge sharing and professional training to foster collaboration with local research institutions. WHX 2026 was held from February 9 to 12, 2026, at Dubai Expo City, where INSILICO was invited by EDE to deliver a keynote speech at its exhibition booth, showcasing the core role of AI and automation technologies in accelerating drug development through interactive demonstrations. Previously, INSILICO established an AI and quantum computing drug R&D center in Abu Dhabi. As one of the largest AI-driven research hubs in the Middle East, the center is dedicated to advancing drug discovery and the development of its Pharma.AI platform, strengthening cross-disciplinary innovation in AI and life sciences.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INSILICO Shares Surge Nearly 6% Following Strategic Collaboration Intent with UAE Health Authority</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINSILICO Shares Surge Nearly 6% Following Strategic Collaboration Intent with UAE Health Authority\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-05 10:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INSILICO (03696) rose nearly 6%, with gains reaching 5.81% at the time of writing, trading at HK$54.65 and recording a turnover of HK$40.6374 million. On March 5, the company announced via its official social media account that it has formally signed a memorandum of understanding (MOU) with the UAE's Emirates Drug Establishment (EDE) to deepen the development of the pharmaceutical industry in the UAE through AI-driven drug discovery and development technologies. The collaboration was established during WHX 2026 (World Health Expo 2026), aiming to leverage the strengths of both parties and expand cooperation areas, with the goal of building the UAE's independent pharmaceutical R&D capabilities, supporting the evaluation and management of innovative medical products, and enabling knowledge sharing and professional training to foster collaboration with local research institutions. WHX 2026 was held from February 9 to 12, 2026, at Dubai Expo City, where INSILICO was invited by EDE to deliver a keynote speech at its exhibition booth, showcasing the core role of AI and automation technologies in accelerating drug development through interactive demonstrations. Previously, INSILICO established an AI and quantum computing drug R&D center in Abu Dhabi. As one of the largest AI-driven research hubs in the Middle East, the center is dedicated to advancing drug discovery and the development of its Pharma.AI platform, strengthening cross-disciplinary innovation in AI and life sciences.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VT","symbol_name":"世界全股市ETF-Vanguard","start_time":0,"source_url":"","article_id":"1163799838","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163799838","pubTimestamp":1772678322,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"INSILICO (03696) rose nearly 6%, with gains reaching 5.81% at the time of writing, trading at HK$54.65 and recording a turnover of HK$40.6374 million. On March 5, the company announced via its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VT":"世界全股市ETF-Vanguard","VXUS":"国际股票ETF-Vanguard","BK4588":"碎股","BK4585":"ETF&股票定投概念","03696":"英矽智能","BK1141":"生命科学工具和服务"},"translate_title":"INSILICO与阿联酋卫生局达成战略合作意向后股价飙升近6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1,"VT":1,"VXUS":1},"content_text":"INSILICO (03696) rose nearly 6%, with gains reaching 5.81% at the time of writing, trading at HK$54.65 and recording a turnover of HK$40.6374 million. On March 5, the company announced via its official social media account that it has formally signed a memorandum of understanding (MOU) with the UAE's Emirates Drug Establishment (EDE) to deepen the development of the pharmaceutical industry in the UAE through AI-driven drug discovery and development technologies. The collaboration was established during WHX 2026 (World Health Expo 2026), aiming to leverage the strengths of both parties and expand cooperation areas, with the goal of building the UAE's independent pharmaceutical R&D capabilities, supporting the evaluation and management of innovative medical products, and enabling knowledge sharing and professional training to foster collaboration with local research institutions. WHX 2026 was held from February 9 to 12, 2026, at Dubai Expo City, where INSILICO was invited by EDE to deliver a keynote speech at its exhibition booth, showcasing the core role of AI and automation technologies in accelerating drug development through interactive demonstrations. Previously, INSILICO established an AI and quantum computing drug R&D center in Abu Dhabi. As one of the largest AI-driven research hubs in the Middle East, the center is dedicated to advancing drug discovery and the development of its Pharma.AI platform, strengthening cross-disciplinary innovation in AI and life sciences.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1163799838","isCrawlerRequest":true}